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Abstract
Background: To compare diabetes risk assessment tools in estimating risk of developing type 2 diabetes (T2DM) and to
evaluate cardiometabolic risk profiles in a middle-aged Irish population.
Methods: Future risk of developing T2DM was estimated using 7 risk scores, including clinical measures with or without
anthropometric, biological and lifestyle data, in the cross-sectional Mitchelstown cohort of 2,047 middle-aged men and
women. Cardiometabolic phenotypes including markers of glucose metabolism, inflammatory and lipid profiles were
determined.
Results: Estimates of subjects at risk for developing T2DM varied considerably according to the risk assessment tool used
(0.3% to 20%), with higher proportions of males at risk (0–29.2% vs. 0.1–13.4%, for men and women, respectively).
Extrapolated to the Irish population of similar age, the overall number of adults at high risk of developing T2DM ranges
from 3,378 to 236,632. Numbers of non-optimal metabolic features were generally greater among those at high risk of
developing T2DM. However, cardiometabolic profile characterisation revealed that only those classified at high risk by the
Griffin (UK Cambridge) score displayed a more pro-inflammatory, obese, hypertensive, dysglycaemic and insulin resistant
metabolic phenotype.
Conclusions: Most diabetes risk scores examined offer limited ability to identify subjects with metabolic abnormalities and
at risk of developing T2DM. Our results highlight the need to validate diabetes risk scoring tools for each population studied
and the potential for developing an Irish diabetes risk score, which may help to promote self awareness and identify high
risk individuals and diabetes hot spots for targeted public health interventions.
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Introduction
Type 2 diabetes mellitus (T2DM) is a common metabolic
condition associated with increased morbidity and mortality,
largely due to increased cardiovascular risk [1–3]. The increasing
global prevalence of T2DM represents a major public health
concern. Current estimates predict in excess of 400 million
individuals with T2DM worldwide by 2030 [4]. The diabetes
epidemic has been driven by complex gene-environment interac-
tions. Genetic factors contribute almost 50% towards T2DM risk.
Obesity and weight gain are also directly related to T2DM risk [5].
The pathway from obesity, impaired fasting glucose (IFG) and
insulin resistance towards impaired glucose tolerance (IGT) and
overt T2DM represents a progressive phenotype. T2DM is
preventable through lifestyle changes in diet and physical activity
[6,7], and subjects with IFG and IGT have been a key focus of
prevention studies [6,8,9]. However population screening for IGT
is time consuming and cost prohibitive. Moreover longitudinal
studies have shown that only about half of subjects with IFG and/
or IGT progress to T2DM and approximately 40% of subjects
who developed T2DM had normal glucose tolerance at baseline
[10]. Thus developing more cost-effective, simple and fast
population applicable screening methods to identify those at risk
and who might benefit from targeted prevention is a current
challenge.
Various diabetes risk assessment tools have been developed in
numerous populations, either for self-assessment relying on readily
available health information; others need to be completed by the
physician and require clinical and/or biological data [11–16].
Using a variety of risk factors, weighting schemes and thresholds
such risk scores aim to identify those with prevalent but
undiagnosed diabetes and/or incident diabetes. Considering the
long asymptomatic period preceding the manifestation of T2DM,
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early identification of individuals at increased risk could allow
earlier diagnosis, enabling earlier targeted interventions such as
implementation of healthy lifestyle changes in nutritional behav-
iour and exercise or pharmacotherapy, thus attenuating develop-
ment of diabetes and its associated cardiometabolic complications.
The prevalence of T2DM in an Irish primary care based sample in
1998 was estimated to be 3.9%; 30% of whom were undiagnosed
[17]. A recent report from the Irish Institute of Public Health
suggested a prevalence of 8.9% and predicted a 30% increase over
the next decade [18]. We recently examined the prevalence of
diagnosed and undiagnosed diabetes within the Mitchelstown
cohort [19]. Estimates of 8.5% were comparable to that from the
nationally representative general population [20]. However a
considerable proportion (41%) of diabetes cases were undiagnosed,
emphasising the need for more effective detection strategies. No
diabetes risk scores have been applied to or developed in an Irish
population where diabetes care represents approximately 10% of
the Republic of Irelands total health expenditure [21]. Therefore
the primary aims of this study were to compare the results of
diabetes risk scores based on a range of anthropometric, clinical,
biological, family history and/or lifestyle data in estimating risk of
developing T2DM in a middle-aged cohort and to characterise
cardiometabolic profiles according to each tool. Secondary
objectives included extrapolation of these findings to the Irish
population of same age and gender, and assessment of the impact
of different diagnostic criteria to exclude T2DM (fasting plasma
glucose (FPG) and haemoglobin A1c (HbA1c) on estimated diabetes
risk.
Methods
Study Design and Population
The Cork and Kerry Diabetes and Heart Disease Study (Phase
II) was a single centre, cross-sectional study conducted between
2010 and 2011 [22]. A population representative random sample
was recruited from a large primary care centre (Livinghealth
Clinic) in Mitchelstown, County Cork, Ireland, which includes 8
general practitioners and serves a catchment area of approxi-
mately 20,000 with a mix of urban and rural residents. Mitchels-
town cohort participants were randomly selected from all
registered attending patients in the 50–69 year age group. In
total 3,807 potential participants were selected from the practice
list. Following exclusion of duplicates, deaths and ineligibles, 3,043
were invited to participate in the study and of these 2,047 (49.2%
male) completed the questionnaire and physical examination
components of the baseline assessment (response rate 67%). While
almost 100% of the cohort were in the 50–69 year age bracket it
should be noted that a small number of subjects outside of this age
group, mainly subjects who celebrated their 70th birthday during
the cohort recruitment, were included. Ethics committee approval
conforming to the Declaration of Helsinki was obtained from the
Clinical Research Ethics Committee of University College Cork.
All participants provided written informed consent. Individuals
with doctor diagnosed diabetes or FPG $7.0 mmol/L were
excluded, resulting in 1,862 non-diabetic individuals at risk of
developing T2DM who were included in the current study. For
comparative purposes HbA1c was also used to define T2DM
(HbA1c $6.5% and/or treatment for diabetes), resulting in 1,823
non-diabetic individuals for analyses. Participants with missing
data for FPG, HbA1c or diabetes treatment were excluded. All
collected source data are maintained and stored at the study
research office, in the Department of Epidemiology and Public
Health, University College Cork. Specific proposals for future
collaboration for which data would be made available would be
welcomed. Further information can be found on the Centre for
Diet and Health Research website, http://www.ucc.ie/en/hrbc/
projects/cluster3 or by contacting the corresponding author.
Clinical and Anthropometric Data
All participants attended the clinic in the morning after an
overnight fast (minimum 8 h). Fasting blood samples were taken
on arrival. Participants completed a General Health Question-
naire (GHQ), a Food Frequency Questionnaire (FFQ) and the
International Physical Activity Questionnaire (IPAQ). Data on
age, gender, family history, medication/medical history and
lifestyle factors was gathered through a self-completed GHQ.
Participants answered questions regards personal and family
diabetes diagnosis/treatment and personal hypertension diagno-
sis/treatment. Corticosteroid use was also used in the current
analysis. Smoking status was defined as never, former and current
smokers. Alcohol consumption included questions regards past
and current intake to define drinkers, never or former drinkers.
Diet was assessed using a modified version of the EPIC FFQ,
validated for use in the Irish population, which was previously
used in the Cork and Kerry Phase 1 study [23]. Participants were
classified according to number of daily portions of fruit and
vegetable, red meat (150 g/day), wholegrain bread (50 g/day),
coffee (150 g/day) and moderate alcohol consumption (10–40 g/
day). Physical activity levels were assessed using the short form
IPAQ [24]. Subjects were defined as having low, moderate or high
levels of physical activity. Blood pressure and resting pulse were
measured according to the European Society of Hypertension
Guidelines using an Omron M7 Digital BP monitor on the right
arm, after a 5 minute rest in the seated position. The average of
the second and third measurements was used for analyses.
Anthropometric measurements were recorded with calibrated
instruments according to a standardised protocol. Body weight was
measured in kilograms without shoes, to the nearest 100 g, using a
Tanita WB100MA weighing scales (Tanita Corporation, IL,
USA). Height was measured in centimetres to 1 decimal place
using a Seca Leicester height gauge (Seca, Birmingham, UK).
Body mass index (BMI) was calculated. Hip circumference at
widest point and mid-way waist circumference were measured in
centimetres to 1 decimal place using a Seca 200 measuring tape
(Seca, Birmingham, UK). The average of two measures was used
for analyses.
Biological Analyses
Plasma and serum were prepared from fasting blood samples.
FPG concentrations were determined using a glucose hexokinase
assay and serum high density lipoprotein (HDL) cholesterol, low
density lipoprotein cholesterol, triglycerides and uric acid levels
were analysed using enzymatic colorimetric tests (Olympus Life
and Material Science Europa Ltd., Lismeehan, Co. Clare, Ireland)
on an Olympus 5400 automatic analyser (Olympus Diagnostica
Gmbh, Hamburg, Germany) by Cork University Hospital
Biochemistry Laboratory. HbA1c was measured using an auto-
mated high-performance liquid chromatography analyser (Tosoh
HLC-723 (G7), Tosoh Europe N.V, Tessenderlo, Belgium).
Complement component c3 (C3) was determined by immuno-
turbidimetric assay (Rx Daytona; Randox Laboratories, Antrim,
UK). Serum insulin, C reactive protein (CRP), tumour necrosis
factors aTNF-a
¨
interleukin 6 (IL-6), adiponectin (ACDC), leptin
and plasminogen activator inhibitor-1 (PAI-1)were determined
using a biochip array system (Evidence Investigator; Randox
Laboratories, Antrim, UK). Homeostasis model assessment
(HOMA), a measure of insulin resistance, was calculated as
[(fasting plasma glucose x fasting serum insulin)/22.5] [25].
Diabetes Risk Scores and Cardiometabolic Profiles
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Diabetes Risk Scores
Seven diabetes risk scores were assessed including the 9-year risk
score based on the French DESIR study by Balkau et al., [11], the
UK Cambridge Diabetes Risk Score by Griffin et al., [12], the 10-
year basic risk score, based on lifestyle and clinical information,
and the enhanced risk score which incorporates biological factors
from Kahn et al., [13], the 5–10 year Finnish Diabetes Risk Score
(FINDRISC) [14], the 5-year German Diabetes Risk Score by
Schulze et al., [15] and finally the 8-year risk score from Wilson
et al., based on the Framingham Offspring Study [16]. Further
details regarding the study populations and variables used in each
risk score are presented in Tables S1 and S2.
Statistical Analysis
Proportions of individuals at high risk of developing T2DM
were calculated according to each diabetes risk score and
expressed as percentages and 95% confidence intervals (CI).
Cardiometabolic and inflammatory markers were assessed for
normality of distribution, and skewed variables were normalised
by log10 transformation as appropriate. Differences between
groups were analyzed by independent t-tests or Mann Whitney
U tests. Non-optimal cardiometabolic risk features were deter-
mined using the NCEP ATP III metabolic syndrome (MetS)
criteria [26]. Standard BMI and 75th percentile cut-offs were used
for HOMA and for generating a composite inflammatory score
based on C3, CRP, TNF-a
¨
IL-6, ACDC and leptin concentrations.
The combined number of each of these non-optimal features
according to each score was then compared between individuals
classified as at high risk of developing T2DM and those classified
as not being at high risk by independent t-tests. For the
extrapolation analysis we used current national age-group specific
diabetes prevalence estimates [18] to the population estimates for
2011 provided by the Central Statistics Office (www.cso.ie) to
ascertain the number of non-diabetic subjects in Ireland. Next the
number of at risk subjects was estimated for each risk score by
applying the age-group and gender-specific estimates obtained in
the Mitchelstown cohort to the corresponding diabetes-free
population. Correlations and pair-wise comparison of agreement
between risk scores were assessed by Spearman correlation
coefficient and Cohen’s kappa, respectively. Statistical analyses
were carried out using SPSS version 18.0 for Windows (SPSS Inc,
Chicago, IL. USA).
Results
Estimated Proportion of Mitchelstown Participants at
High Risk for T2DM
Characteristics of the non-diabetic individuals (defined by FPG)
included in the analyses are presented in Table S3. Following
exclusion of missing data and existing T2DM the remaining 1,862
and 1,823 non-diabetic participants (by FPG and HbA1c cut-offs,
respectively) were used in the analyses. The proportion of
individuals in the Mitchelstown cohort at high risk for developing
T2DM is presented in Table 1. Estimates varied considerably
between scores (from 0.3% [Wilson] to 20% [Griffin]). Higher risk
was detected in men relative to women with the exception of the
Balkau risk score, which did not identify any males at increased
risk of developing T2DM. Choice of diagnostic criteria to exclude
diabetes did not significantly impact on estimated incidence.
Similar but slightly lower numbers of high risk males and females
were identified using the Wilson, Balkau, FINDRISC, Schulze and
Kahn Basic scores when HbA1c was used to exclude T2DM. In
contrast higher proportions of at risk subjects were identified using
the Kahn Enhanced score, whereas identical percentage values
were obtained using the Griffin score. Examination of estimated
risk according to age group across each risk score consistently
showed lowest risk in the 45–54 year age group (Figure 1).
Greatest risk was identified in the 65–74 year olds according to the
FINDRISC, Schulze and Griffin risk scores, whereas the Balkau
and both Kahn risk scores detected highest risk in the 55–64 year
olds. Extrapolated to the Irish population of similar age (Table 2),
the overall number of adults at high risk of developing T2DM
ranges from 3,378 to 236,632. Exclusion of the lowest scores
(Wilson and Balkau) yields higher estimates ranging from 80,381
to 233,431.
Cardiometabolic Risk Profiles According to Diabetes Risk
Scores
Greater numbers of non-optimal metabolic features were
generally observed among individuals classified as at high risk of
developing T2DM, with the exception of the Wilson score
(Figure 2). Significant differences between subjects were observed
for the Griffin (P,0.001) and Kahn Basic risk scores (P,0.005).
Closer examination of individual inflammatory profiles, clinical
characteristics, anthropometric measurements and markers of lipid
and glucose homeostasis according to diabetes risk classification
are presented in Table 3. Only the Griffin risk score identified a
range of significant differences. Compared to their low risk
counterparts individuals at high risk of developing T2DM had
larger waist circumference, higher BMI, were more hypertensive,
which may be expected as these variables are included in the risk
score. Interestingly these subjects also displayed a more pro-
inflammatory, pro-thrombotic, dysglycaemic and more insulin
resistant metabolic phenotype.
Comparison between Diabetes Risk Scores
We examined whether the same individuals were classified as
high risk according to the different scores. Despite moderate to
strong positive correlations between scores (Table S4), indicating
similar ordering of subjects, agreement levels between risk score
classifications were low. Comparing the two lifestyle factor based
risk scores (FINDRISC and Schulze) revealed some degree of
concordance (Figure 3A). These scores identified a total of 283
subjects at risk: n = 226 (Schulze) and n= 131 (FINDRISC). Of the
131 participants at risk according to FINDRISC 74 (56.5%) of
these were simultaneously classified as at risk by Schulze (Cohen’s
kappa 0.37, p,0.001). Comparison of the clinical risk scores
(Balkau, Wilson and Kahn Enhanced) was disappointing
(Figure 3B), even after exclusion of the Wilson score, as only 14
(29.2%) of the 48 subjects classified as at risk according to Balkau
were similarly classified by Kahn Enhanced which identified 351
subjects as being at risk. Comparison of the risk scores which led to
the greatest prevalence (Kahn Basic and Enhanced, Griffin)
revealed that only 131 subjects (20.9%) were simultaneously
classified as high risk according to all three of these scores
(Figure 3C).
Discussion
Several diabetes risk scores have been developed as screening
tools to identify individuals either with undiagnosed T2DM and/
or at high risk of developing T2DM. However it is not clear which
risk scores are the best or who should be screened using such
scores. Comparative data on the performance of a range of
diabetes risk scores in a given population is limited. Therefore the
aims of this study were to compare the results of diabetes risk
assessment tools based on a range of anthropometric, clinical,
biological, family history and/or lifestyle data in estimating risk of
Diabetes Risk Scores and Cardiometabolic Profiles
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developing T2DM in a middle-aged Irish population and to
characterise their cardiometabolic profiles according to each tool.
Estimates of at risk subjects in the Mitchelstown cohort varied
considerably according to the risk score used, with higher
proportions of high risk males identified. Extrapolation of these
risk estimates to the Irish population revealed that between 3,378
to 236,632 adults are at high risk of developing T2DM. Similar
but slightly lower numbers of at risk males and females were
identified when HbA1c rather than FPG was used to exclude
diabetic subjects. The inclusion, or indeed exclusion, of certain
factors, differential weighting of each variable, variation in high
risk thresholds and differences in populations used to develop these
scores contributed to the wide range of risk estimates obtained.
While the risk scores were based on a range of variables, some
factors were shared between scores. The constellation of hyper-
tension, obesity, dysglycaemia and dyslipidaemia characterise the
MetS which is associated with increased T2DM risk. Thus it was
expected that these phenotypes would feature in diabetes risk
scores. Only hypertension and a measure of obesity or adiposity
were included in all scores. Most scores included personal or
family history and some included biological parameters such as
lipids and FPG. Modifiable risk factors including physical activity
and moderate alcohol consumption are associated with reduced
T2DM risk [27,28], whereas smoking is related to increased risk
[29]. Smoking was included in the Balkau, Schulze, Kahn Basic
and Griffin scores. Alcohol was examined in the Schulze score and
the Kahn Enhanced score. Diet is major modifiable risk factor
associated with diabetes risk [30–33]. Only the FINDRISC and
Schulze scores took diet and physical activity into account.
All of the risk scores, except for Kahn et al., [13] and Wilson
et al., [16], were developed in European populations. One might
expect these scores to be applicable to an Irish population.
Figure 1. Comparison of the proportion of Mitchelstown cohort subjects at risk of developing T2DM according to each diabetes
risk score and age group. Lowest risk was identified in the 45–54 year old group (black bars) for every diabetes risk score. Greatest risk was
detected in the 55–64 year olds (white bars) for the Balkau and both Kahn risk scores, whereas the FINDRISC, Schulze and Griffin risk scores
demonstrated greatest risk in the 65–74 year old individuals (grey bars).
doi:10.1371/journal.pone.0078950.g001
Table 1. Proportion (percentage and 95% confidence interval) of subjects at risk of developing T2DM in the Mitchelstown cohort
according to each diabetes risk score by gender using FPG and HbA1c to exclude existing diabetes.
N Wilson Balkau FINDRISC Schulze Kahn Enhanced Kahn Basic Griffin
FPG
All 1862 0.3 (0.06–0.58) 2.6 (1.9–3.3) 7.0 (5.9–8.2) 12.1 (10.6–13.6) 18.9 (17.1–20.6) 18.9 (17.1–20.7) 20.0 (18.2–21.9)
Male 896 0.6 (0.07–1.0) 0.0 (0.0) 7.8 (6.0–9.6) 15.1 (12.7–17.4) 24.8 (21.9–27.6) 27.1 (24.2–30.0) 29.2 (26.3–32.2)
Female 966 0.1 (0.01–0.3) 5.0 (3.6–6.4) 6.3 (4.8–7.9) 9.4 (7.6–11.3) 13.4 (11.2–15.5) 11.3 (9.3–13.3) 11.5 (9.5–13.5)
HbA1c
All 1823 0.2 (0.01–0.35) 2.5 (1.8–3.2) 6.7 (5.5–7.8) 11.6 (10.2–13.1) 19.1 (17.3–20.9) 18.1 (16.3–19.9) 20.0 (18.2–21.9)
Male 872 0.2 (0.01–0.6) 0.0 (0.0) 7.8 (6.0–9.6) 14.7 (12.3–17.1) 25.6 (22.7–28.5) 26.1 (23.2–29.1) 28.9 (25.9–31.9)
Female 951 0.1 (0.01–0.3) 4.7 (3.4–6.1) 5.7 (4.2–7.2) 8.8 (7.0–10.6) 13.1 (11.0–15.3) 10.7 (8.8–12.7) 11.9 (9.8–13.9)
doi:10.1371/journal.pone.0078950.t001
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However increasing evidence suggests that not only can risk scores
not be generalised from one country to another but that risk scores
developed and used in the same country produce conflicting
results [34–36]. The lowest risk estimates (0.3–2.6%) were
obtained from the Wilson and Balkau scores, which are based
on biological and clinical parameters, respectively. It should be
noted that despite FPG being significantly predictive for diabetes
in the Balkau study [11], it was not included in the risk score.
Importantly age was not included in either score. Age is highly
correlated with adiposity, hypertension and glucose concentra-
tions. Waist circumference and hypertension appear in the Balkau
risk score, but the lack of both age and FPG in the model may
partly account for the low estimates. Also noteworthy is the finding
that only women were identified as being at risk according to the
Balkau score, which may introduce a gender bias to analysis based
on this score. Furthermore the Framingham Offspring Study, from
which the Wilson risk score was developed, was initiated more
than 20 years ago. Thus it could be argued that their data may not
be an accurate reflection of current diabetes trends with respect to
lifestyle behaviour.
The highest prevalence estimates (18.9–20%) were obtained for
the Griffin and Kahn scores (Basic and Enhanced), which all
include age. Alcohol intake was only included in the Kahn
Enhanced risk score, which pooled non-drinkers and former
drinkers into a single group, thereby not taking the U-shaped
association between alcohol intake and T2DM risk into account.
The Griffin score was based on a Caucasian UK population aged
40–79 years, whereas the Kahn US population (45–64 years of
age) included 22.8% black participants. Different scoring was
applied according to race, which would not impact on our
findings, but the accuracy of the Kahn scores in predicting
diabetes risk for people older than 64 years of age has not been
confirmed. Indeed comparison of risk estimates from each score
according to age group revealed lowest risk in the 45–54 year old
age group for all scores. It is thought that over the next 25 years
the greatest increase in T2DM in developed countries will be
observed in the over 65 year old age group [37]. In keeping with
this greatest risk was identified in the 65–74 year olds by all scores,
except for the Balkau and both Kahn risk scores which detected
greatest risk in the 55–64 year olds. The lack of age in the Balkau
score and younger population used to derive the Kahn scores may
explain these discrepancies. Despite the above issues the sequential
application of the Kahn Basic and Enhanced scores may hold
some value in identification of at risk subjects. A recent prospective
study of a large elderly UK population demonstrated that a two-
stage approach, consisting of an initial simple clinical assessment to
identify individuals who would benefit from further routine blood
testing, represents an easy and cost-effective way of detecting high
risk individuals [38].
Lifestyle and pharmacological interventions can delay or
prevent the development of T2DM [6,7,9,39]. Lifestyle modifica-
tion, in particular weight loss and physical activity, can signifi-
cantly reduce diabetes risk [6,7,9] and can be even more effective
than medication [6,39]. Although modifiable risk factors may be
more informative to include in risk scores, with a view to risk
reduction, most of the current risk scores are predominantly based
on non-modifiable risk factors. Only the FINDRISC and Schulze
scores include diet and physical activity. The FINDRISC score is
the most widely used diabetes risk score which has also been
successfully implemented in prevention programs [40]. Interest-
ingly both of these scores generated risk estimates consistent with
recent 10 year predictions for the Irish population [18]. Higher
risk estimates were obtained for the Schulze score, which
additionally includes moderate alcohol consumption, smoking
behaviour and dietary consumption of red meat, wholegrain and
coffee which are associated with diabetes risk [30–33]. Compar-
ison of these scores demonstrates that over half of the FINDRISC
at risk subjects were similarly classified by the Schulze score. This
may be expected for risk scores which share the same variables.
However comparison of the three clinical risk scores (Balkau,
Wilson and Kahn Enhanced) revealed much lower concordance,
even after exclusion of the Wilson score. Agreement between the
risk scores which led to the greatest prevalence (Griffin, Kahn
Basic and Enhanced) was also poor, suggesting that different risk
scores identify different individuals to be at risk.
While the predictive ability of these diabetes risk scores cannot
be assessed at present the planned longitudinal follow-up of the
Mitchelstown cohort will enable their predictive and discrimina-
tive value to be ascertained. Nevertheless we examined the
predictive value of these scores in the Cork and Kerry Phase I
Study, which was initiated in 1998 (n= 1018) and re-screened in
2008 (n= 359) [41,42]. Risk estimates were consistent with the
current work, with the exception of the Schulze score which
estimated the greatest risk (Table S6). Correct classification of the
Table 2. Extrapolation of the Mitchelstown findings to the Irish population: numbers of individuals at high risk of developing
T2DM by each diabetes risk score according to gender and age group.
Gender and age
group Irish population Wilson Balkau FINDRISC Schulze Kahn Enhanced
Kahn
Basic Griffin
Male
45–54 280,297 1,205 0 9,810 21,022 52,976 52,976 46,810
55–64 217,421 1,739 0 19,350 31,570 68,922 60,008 64,139
65–74 136,399 0 0 13,913 35,191 34,509 33,691 60,152
Total 634,117 2,945 0 43,074 87,783 156,408 146,675 171,101
Female
45–54 283,278 0 9,065 12,464 13,597 9,065 18,130 9,065
55–64 216,791 434 12,574 14,959 19,728 34,687 35,987 23,847
65–74 141,208 0 7,060 9,885 22,734 12,709 19,204 32,619
Total 641,277 434 28,699 37,307 56,060 56,460 73,321 65,531
Overall total 1,275,394 3,378 28,699 80,381 143,843 212,868 219,996 236,632
doi:10.1371/journal.pone.0078950.t002
Diabetes Risk Scores and Cardiometabolic Profiles
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e78950
new T2DM cases identified in the re-screen varied considerably
across scores. The Kahn Enhanced score achieved the best
predictive value. The high proportion of subjects identified as at
risk but who did not develop T2DM over the 10 year follow-up
underscores the poor sensitivity and positive predictive value of
existing diabetes risk scores.
Limited comparisons of diabetes risk scores in combination with
cardiometabolic profiling exist. A Swiss comparative study
examining the same diabetes risk scores, except for the Schulze
score, also reported wide variation in predicted risk estimates, with
the lowest risk identified by the Wilson and Balkau scores and the
greatest risk by the FINDRISC and Griffin scores [36]. No dietary
or second-degree family history of diabetes data were available for
this study, thus the authors adapted the FINDRISC score to
account for this which might have impacted on their findings. No
cardiometabolic profiling was undertaken. Furthermore the
relatively low participation rate (41%) may limit the applicability
of their findings to the general population. Mann et al., analysed
the validity of 3 diabetes risk score models in predicting risk in a
multi-ethnic cohort [35]. While each model maintained high
discriminative ability, each required recalibration when applied to
a multi-ethnic cohort. While ethnicity was not detailed, race is not
Table 3. Cardiometabolic profiles according to each diabetes risk scorea.
Wilson Balkau FINDRISC Schulze Kahn Enhanced Kahn Basic Griffin
Age (years) At risk 57.365.5a 59.566.4 60.465.5 60.465.5 59.865.6 59.965.5 62.365.1c
Not at risk 59.765.2 59.765.5 59.665.4 59.665.4 59.665.5 59.665.5 59.065.4
BMI (kg/m2) At risk 28.563.8 28.864.6 28.764.6 28.764.7 28.764.7 28.864.7 32.364.1c
Not at risk 28.464.6 28.464.5 28.464.1 28.464.2 28.364.1 28.364.4 27.464.2
Waist circumference (cm) At risk 97.6613.1 97.7613.1 97.0613.3 97.2613.3 96.9613.4 97.5613.2 107.2610.18c
Not at risk 96.3613.9 96.2614.6 96.2611.2 96.1612.3 96.1611.9 96.0612.9 93.5612.14
SBP (mmHg) At risk 12317 124617b 129617 130618 129617 129617 135617c
Not at risk 130616 130613 129617 129617 130616 129616 128617
DBP (mmHg) At risk 74610b 78610b 80611 80611 80610 80610 82610c
Not at risk 8066 8069 80610 80610 8069 80610 80610
FPG (mmol/L) At risk 4.6060.57 5.0760.68 4.9660.57 4.9860.62 5.0360.57 5.0360.61 5.2360.67c
Not at risk 4.9860.53 4.9860.56 4.9860.54 4.9860.58 4.9760.56 4.9760.56 4.9360.52
HbA1c (%) At risk 5.4060.49 5.8160.37b 5.6960.37 5.7360.35 5.7260.38 5.9260.38 5.8560.41c
Not at risk 5.7160.35 5.7160.35 5.7160.34 5.7060.35 5.7060.34 5.7160.34 5.6760.32
Insulin (mIU/ml) At risk 12.09613.3 12.0968.98 10.4869.07 12.16611.4 11.5669.88 11.71610.50 16.21612.10c
Not at risk 10.8068.98 10.7769.56 10.8368.01 10.6268.61 10.6468.78 10.6068.61 9.4667.50
HOMA-IR At risk 2.3462.26 2.8762.60 2.4062.22 2.7962.39 2.6862.62 2.6962.65 3.8463.11c
Not at risk 2.4762.27 2.4662.24 2.4762.40 2.4262.15 2.4162.16 2.4162.15 2.1361.86
HDL-C (mmol/L) At risk 1.5260.58 1.4160.37 1.4960.37 1.4560.37 1.4660.37 1.4360.37 1.2860.32c
Not at risk 1.4660.37 1.4660.36 1.4660.37 1.4760.37 1.4660.37 1.4760.37 1.5160.37
TAG (mmol/L) At risk 1.4560.81 1.5260.82 1.4060.81 1.4460.96 1.4960.98b 1.4860.95b 1.6960.98c
Not at risk 1.3961.15 1.3860.78 1.3960.83 1.3860.79 1.3660.77 1.3660.78 1.3160.74
CRP (ng/ml) At risk 1.5663.67 2.5563.65 2.1763.72 2.1863.75 2.4363.70 2.3663.74 2.7864.23c
Not at risk 2.3461.15 2.3464.27 2.3563.02 2.3663.00 3.3263.56 2.3463.36 2.2163.46
C3 (mg/dl) At risk 138.9624.4 143.4630.6 138.4624.3 138.4624.7b 139.8624.3c 139.0625c 141.2623.4c
Not at risk 135.4621.2 135.2624.2 135.2626.7 135.0622.7 134.5624.6 134.6624.2 133.9624.4
TNF-a(pg/ml) At risk 5.2762.49 6.0962.50 6.4862.55 6.5062.45 6.5062.51 6.5362.71 6.9462.88c
Not at risk 6.3161.72 6.3161.80 6.2962.49 6.2662.77 6.2562.41 6.2562.43 6.1362.34
IL- 6 (pg/ml) At risk 2.4064.96 2.8164.98 3.6464.83 3.0565.05 3.2465.33 3.3866.01 3.9064.88c
Not at risk 2.9061.55 2.9063.51 2.8463.21 2.8864.94 2.8264.85 2.7964.67 2.6264.85
Adiponectin (ng/ml) At risk 6.5365.44 6.5563.95 5.9463.96 5.7164.03 5.9864.58 5.7163.96 4.4864.10c
Not at risk 5.8163.95 5.8064.08 5.8164.09 5.8363.95 5.7863.80 5.8463.93 6.1863.04
Leptin (ng/ml) At risk 1.6161.28 2.9966.34 3.0163.44 2.9863.57 2.7663.58 2.9264.09 3.7564.10
Not at risk 3.1061.20 3.1064.46 3.0963.22 3.1063.43 3.1763.01 3.1363.03 2.9163.93
PAI-1 (ng/ml) At risk 25.92612.71 29.27612.70 27.64612.75 27.79612.75 28.01612.79 27.61612.73 29.92613.26c
Not at risk 27.22611.14 27.17612.61 27.18611.95 27.14612.30 27.03612.25 27.12612.56 26.53612.42
aValues are presented as means 6 SD.
bRepresents P value ,0.05.
cRepresents P value ,0.001.
doi:10.1371/journal.pone.0078950.t003
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an issue in the current study as there were no non-white
participants in the Mitchelstown cohort. Given the relationship
between inflammation and insulin resistance it is reasonable to
hypothesize that systemic low-grade inflammation may also
contribute to T2DM risk. Elevated concentrations of CRP, IL-6
and PAI-1 have been associated with increased risk of incident
T2DM [43–46]. Importantly we examined cardiometabolic
profiles including a range of inflammatory markers in the current
work. In contrast to a previous report that the FINDRISC score
can identify undetected abnormal glucose tolerance and metabolic
syndrome [47], only the Griffin risk score clearly differentiated the
high risk subjects who displayed a more obese and hypertensive
profile, as expected as these factors are included in the risk score.
Of note these high risk subjects also displayed a more pro-
inflammatory, pro-thrombotic, dysglycaemic and more insulin
resistant metabolic profile compared to their not at risk
counterparts. Our findings suggest that the Griffin score, which
also identified the greatest number of high risk subjects, may be the
most clinically useful in terms of identifying individuals at greatest
risk of T2DM and related metabolic perturbations.
Our study has several strengths including a high participation
rate (67%), inclusion of questionnaires to assess dietary and
lifestyle behaviours, detailed family and medical histories, exten-
sive biochemical profiling and collection of anthropometric
measurements which allowed us to generate diabetes risk scores
using a range of anthropometric, clinical, biological and/or
lifestyle factors and also to compare cardiometabolic profiles of
at risk individuals according to each score which has not been
achieved in comparative studies to date [35,36]. Notwithstanding
these strengths some limitations can be identified. Overall gender
distribution very closely matched that of the Irish population in the
45–74 year age group (Table S5), however when age category was
Figure 2. Number of non-optimal metabolic features among subjects according to each diabetes risk score. Significant differences
between individuals classified as at high risk of developing T2DM (black bars) and those classified as not being at high risk (white bars) were observed
for the Griffin (P,0.001) and Kahn Basic risk scores (P,0.005).
doi:10.1371/journal.pone.0078950.g002
Figure 3. Agreement regards whether the same individuals were classified as at risk according to the different scores was
examined. Good agreement was achieved between the two risk scores based on lifestyle factors (Figure 3A) with 56.5% of the subjects classified at
risk by FINDRISC being simultaneously classified as at risk by the Schulze risk score. Lower concordance (29.2%) was observed when the three clinical
based risk scores were compared (Figure 3B). Agreement was even lower (20.9%) when the three risk scores which led to the greatest prevalence
were compared (Figure 3C), suggesting that these risk scores do not classify the same people as being at risk.
doi:10.1371/journal.pone.0078950.g003
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taken into consideration the Mitchelstown cohort had less younger
(45–54) and more older (55–64) male and female participants than
the corresponding Irish population, which might be explained by
the fact that our study aimed to primarily recruit middle-aged
subjects by randomly selecting participants in the 50–69 year age
group. Considering the ageing Irish population and that the over
65 year old age group represent the highest risk group [37], our
results may underestimate the true prevalence of Irish adults at risk
for developing T2DM. The range of at risk estimates observed in
our study may also impact on statistical power. Specifically the
small numbers of subjects identified by the Balkau and Wilson
scores may significantly reduce, and conversely the greater
numbers of subjects identified by the Kahn and Griffin scores
may significantly increase statistical power, and thus likelihood to
detect significant findings.
In conclusion, we demonstrate wide variation in the estimates of
middle-aged people at risk for developing T2DM according to
each risk score used suggesting that these risk assessment tools
require validation for each population under consideration. This
data highlights the need to develop an Irish diabetes risk score
which at an individual level (if designed for self-assessment by a lay
person) could promote self awareness of risk factors and modifiable
risk behaviours and at a national level (if designed for a use by a
health professional) could identify diabetes hot spots for targeted
public health interventions. Early identification of high risk
individuals could allow earlier diagnosis and personalised and/or
public health targeted interventions, thus attenuating the devel-
opment of diabetes and associated cardiometabolic complications.
For example, risk stratification using a two step approach
consisting of a preliminary assessment based on a risk score
followed by more in depth biological and clinical measurements
may offer a more cost effective strategy to identify high risk
individuals.
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